MedTrace Logo

Effect of Smoking on Macrophage-related Chemokines Before and After Non-surgical Treatment of Initial Peri-implantitis

NCT06810401 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-02-05

No results posted yet for this study

Summary

Peri-implantitis is a condition affecting tissues around dental implants, leading to inflammation and bone loss. Smoking is a known risk factor that increases the risk of developing peri-implantitis and reduces treatment success. Smokers often have worse outcomes after treatment compared to non-smokers.

Macrophage activity is crucial for fighting infections, but smoking can impair their function, leading to tissue damage. Smoking reduces blood flow and oxygen levels in tissues, hindering healing. Specific chemokines (CCL-2, CCL-8, CXCL-9, and CCL-3) help direct immune responses by recruiting macrophages and other immune cells to infection sites. Understanding how smoking affects these chemokines is essential for improving peri-implantitis treatment outcomes. Peri-implantitis is a complex condition caused by various factors, which makes it challenging to study how smoking affects the immune response in advanced stages of the disease. This study aims to investigate how smoking influences specific chemical signals associated with the immune response (CCL-2, CCL-8, CCL-3, and CXCL-9) in the fluid around dental implants, both before and after non-surgical treatment. The research will compare smokers to non-smokers during the early stages of peri-implantitis.

Conditions

  • Peri-implantitis

Interventions

PROCEDURE

Debridement of implant surface with titanium curettes and irrigation with sterile saline solution

All patients in both groups received non-surgical treatment of peri-implantitis involving the debridement of hard- and soft accumulations on implant surfaces using titanium curettes (Titanium Implant Scaler 204SD, Hu-Friedy) for 15 minutes, followed by irrigation with sterile saline solution

Sponsors & Collaborators

  • University of Turku

    collaborator OTHER

  • Buse Naz BÜYÜKAKÇALI ALTAY

    lead OTHER

Principal Investigators

  • Ulvi K GURSOY, Prof. · University of Turku

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-28
Primary Completion
2024-10-14
Completion
2024-10-14

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06810401 on ClinicalTrials.gov